你是否曾好奇过，科学家们是如何在微观世界中寻找对抗癌症的新武器的？最近，一条新闻引起了广泛关注：总医院公司取得了名为“TEAD转录因子的新型小分子抑制剂”的专利。这听起来可能有点晦涩难懂，但其实它关系到我们每个人的生命健康。 想象一下，如果你的身体是一座城市，那么细胞就是这座城市的居民。当某些细胞开始不受控制地增殖时，它们就像一群疯狂的破坏者，这就是癌症。而TEAD转录因子就像是这些破坏者的指挥官 ...

SW-682 is an investigational novel, oral, potent, and selective pan-TEAD inhibitor and patients are being enrolled in a Phase 1a trial in Hippo-mutant solid tumors. In July, SpringWorks appointed ...

接下来，研究人员借助多体素模式分析（MVPA: Multivoxel Pattern ...

Jacob Gaylord ran for three second-half touchdowns and rallied Gravette past Gentry in a 4A-1 Conference showdown between ...

The city is debating lifting its long-standing ban on fast food lanes, weighing economic growth against concerns over traffic ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...

Since I started speaking out about the attack on our family shelter, St. Anne’s Place, and the police’s substandard response, much of the conversation has naturally turned to policing. But that’s not ...

The Interdisciplinary Graduate Program in Integrative Biotechnology & Translational Medicine, Yonsei University, Incheon 21983, Republic of Korea ...